RaDVaC Data Explorer
Antiviral database
Virus Taxonomy
← Back to Dashboard
Maviret
NS3/4A protease inhibitor + NS5A inhibitor
Constituent drugs (2)
Glecaprevir
Loading structure...
3D not available
Pibrentasvir
Loading structure...
3D not available
Chemical Identifiers
ClinicalTrials.gov
PubMed
Clinical Development by Virus
1
Hepatitis C virus
HCV
Target: Viral NS3/4A + NS5A
Approved (other)
Preclinical
Phase 2
positive
Phase 3
positive
Approved
Japan
Approval ref (kegg.jp)
Approval ref (pmda.go.jp)
PMDA approved 2017/9/27
fixed-dose combination of Glecaprevir, Pibrentasvir.